Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue.
Tackley G, Kong Y, Minne R, Messina S, Winkler A, Cavey A, Everett R, DeLuca GC, Weir A, Craner M, Tracey I, Palace J, Stagg CJ, Emir U. Tackley G, et al. Among authors: craner m. Neuroimage. 2021 Sep;238:118225. doi: 10.1016/j.neuroimage.2021.118225. Epub 2021 May 30. Neuroimage. 2021. PMID: 34062267 Free PMC article.
Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
Juryńczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M, Waters P, Kuker W, Craner M, Weir A, DeLuca GC, Kremer S, Leite MI, Vincent A, Jacob A, de Sèze J, Palace J. Juryńczyk M, et al. Among authors: craner m. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):132-136. doi: 10.1136/jnnp-2016-314005. Epub 2016 Oct 8. J Neurol Neurosurg Psychiatry. 2017. PMID: 27951522
Foveal changes in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive.
Roca-Fernández A, Oertel FC, Yeo T, Motamedi S, Probert F, Craner MJ, Sastre-Garriga J, Zimmermann HG, Asseyer S, Kuchling J, Bellmann-Strobl J, Ruprecht K, Leite MI, Paul F, Brandt AU, Palace J. Roca-Fernández A, et al. Eur J Neurol. 2021 Jul;28(7):2280-2293. doi: 10.1111/ene.14766. Epub 2021 Mar 23. Eur J Neurol. 2021. PMID: 33547839
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis.
Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S, Hemingway C, Hobart J, Evangelou N, Scolding N, Rog D, Nicholas R, Marta M, Blain C, Young CA, Ford HL, Matthews PM. Dobson R, et al. Among authors: craner m. BMJ Open. 2021 Nov 25;11(11):e050176. doi: 10.1136/bmjopen-2021-050176. BMJ Open. 2021. PMID: 34824113 Free PMC article.
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS).
Dobson R, Craner M, Waddingham E, Miller A, Pindoria J, Cavey A, Blain C, De Luca G, Evangelou N, Ford H, Gallagher P, George K, Geraldes Ramos Dias R, Harman P, Hobart J, King T, Linighan R, MacDougall N, Marta M, Mitchell S, Nicholas R, Rog D, Scalfari A, Scolding N, Webb S, White S, Wilton J, Young C, Matthews PM. Dobson R, et al. Among authors: craner m. Mult Scler Relat Disord. 2022 Jul;63:103894. doi: 10.1016/j.msard.2022.103894. Epub 2022 May 20. Mult Scler Relat Disord. 2022. PMID: 35636271 Free article.
72 results